Freenome is pioneering early cancer detection through its innovative intelligent screening platform, which leverages multiomics technology. This approach integrates various scientific disciplines, including computational biology and machine learning, to identify cancer at its earliest and most treatable stages. By utilizing a standard blood draw, Freenome aims to make cancer screening more accessible and effective, addressing the intrinsic complexity and heterogeneity of cancer. Their commitment to early detection is underscored by a rigorous clinical research program that validates their tests, ensuring they are grounded in robust scientific evidence.

The company is actively conducting several large-scale clinical studies, such as the PREEMPT CRC Study for colorectal cancer and the PROACT LUNG Study for lung cancer, which involve thousands of participants from diverse backgrounds. These studies are designed to validate the performance of their blood-based tests, with the goal of improving screening rates and outcomes for various cancer types. Freenome's focus on early detection not only aims to enhance survival rates but also seeks to redefine the future of cancer screening by making it more accessible to the general population.

United States

Freenome is a private biotech company focused on developing blood tests to detect cancer early and make screening accessible for everyone.

Freenome

Company Details